Reference is made to the circular (the “EGM Circular”) of Ascentage Pharma Group International (the “Company”) and the notice (the “EGM Notice”) of the Extraordinary General Meeting (the “EGM”) of the Company both dated August 31, 2021. Terms used in this announcement shall have the same meanings as those defined in the EGM Circular and the EGM Notice unless the context requires otherwise.

The Board is pleased to announce that at the EGM held on September 20, 2021, the resolutions nos. 1 and 2 as set out in the EGM Notice were duly passed by the Independent Shareholders by way of poll and the resolutions nos. 3(a) to 3(c) were duly passed by the Shareholders by way of poll.

The poll results in respect of the resolutions proposed at the EGM were as follows:

<table>
<thead>
<tr>
<th>Ordinary Resolutions*</th>
<th>Number of votes cast and approximate percentage of total number of votes</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. To consider and approve the proposed grant of RSUs to the Connected Selected Persons.</td>
<td>For: 68,106,989 (95.93%) Against: 2,890,594 (4.07%)</td>
</tr>
<tr>
<td>Ordinary Resolutions*</td>
<td>Number of votes cast and approximate percentage of total number of votes</td>
</tr>
<tr>
<td>----------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| 2. To grant a specific mandate to the directors of the Company to exercise the powers of the Company to allot and issue the underlying Shares of the RSUs proposed to be granted to the Connected Selected Persons, being 92,690 Shares in aggregate. | For: 68,106,989 (95.93%)  
Against: 2,890,594 (4.07%) |
| 3(a). To authorize the directors of the Company to create and issue the Warrants to Innovent. | For: 70,979,083 (99.97%)  
Against: 18,500 (0.03%) |
| 3(b). To grant a specific mandate of the directors of the Company to exercise the powers of the Company to allot and issue the Warrant Shares including the adjustment thereof, upon exercise of the subscription rights attached to the Warrants. | For: 70,979,083 (99.97%)  
Against: 18,500 (0.03%) |
| 3(c). Any one or more of the directors of the Company be and are hereby authorized to do all such acts and things, to sign and execute such documents or agreements or deed on behalf of the Company and to do such other things and to take all such actions as he/she considers or they consider necessary, appropriate, desirable or expedient for the purposes of giving effect to or in connection with the Warrant Subscription Deed and all the transactions in relation to the creation and issue of the Warrants and the allotment and issue of the Warrant Shares and to agree to such variation, amendments or waiver or matters relating thereto (excluding any variation, amendments or waiver of such documents or any terms thereof, which are fundamentally and materially different from those as provided for in the Warrant Subscription Deed and which shall be subject to approval of the shareholders of the Company) as are, in the opinion of any one or more of the directors of the Company, in the interest of the Company and its shareholders as a whole. | For: 70,979,083 (99.97%)  
Against: 18,500 (0.03%) |
As more than 50% of the votes are cast in favour of each of the resolutions, the resolutions nos. 1 and 2 were duly passed by the Independent Shareholders by way of poll and the resolutions nos. 3(a) to 3(c) were duly passed by the Shareholders by way of poll.

Notes:

(1) As at the date of the EGM, the total number of Shares in issue was 263,472,216 Shares.

(2) As disclosed in the EGM Circular, Innovent, who is the holder of 8,823,863 Shares, was required to and did abstain from voting on the resolutions nos. 3(a) to 3(c). Save as disclosed above, (i) there were no Shares entitling the Shareholders to attend and abstain from voting in favour of any resolution at the EGM as set out in Rules 13.40 of the Listing Rules and no other Shareholders were required to abstain from voting at the EGM under the Listing Rules; and (ii) none of the Shareholders had indicated in the EGM Circular that they intended to vote against or to abstain from voting on any resolution at the EGM.

(3) The total number of Shares entitling the Independent Shareholders to attend and vote for or against the resolutions nos. 1 and 2 at the EGM was 263,472,216 Shares.

(4) The total number of Shares entitling the Shareholders to attend and vote for or against the resolutions nos. 3(a) to 3(c) at the EGM was 254,648,353 Shares.

(5) Tricor Investor Services Limited, the Company’s Hong Kong branch share registrar, acted as the scrutineer.

By Order of the Board
Ascentage Pharma Group International
Dr. Yang Dajun
Chairman and Executive Director

Suzhou, the People’s Republic of China, September 20, 2021

As at the date of this announcement, the Board comprises Dr. Yang Dajun as Chairman and executive Director; Dr. Wang Shaomeng, Dr. Tian Yuan, Dr. Lu Simon Dazhong and Mr. Liu Qian as non-executive Directors; and Mr. Ye Changqing, Dr. Yin Zheng, Mr. Ren Wei and Dr. David Sidransky as independent non-executive Directors.

* The full text of the resolutions is set out in the EGM Notice.